289 related articles for article (PubMed ID: 22722022)
1. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
[TBL] [Abstract][Full Text] [Related]
2. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.
Huot P; Johnston TH; Koprich JB; Winkelmolen L; Fox SH; Brotchie JM
Neurobiol Aging; 2012 Jan; 33(1):207.e9-19. PubMed ID: 21051107
[TBL] [Abstract][Full Text] [Related]
3. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
4. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Koprich JB; Fox SH; Johnston TH; Goodman A; Le Bourdonnec B; Dolle RE; DeHaven RN; DeHaven-Hudkins DL; Little PJ; Brotchie JM
Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
[TBL] [Abstract][Full Text] [Related]
5. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Huot P; Johnston TH; Koprich JB; Aman A; Fox SH; Brotchie JM
J Pharmacol Exp Ther; 2012 Aug; 342(2):576-85. PubMed ID: 22619253
[TBL] [Abstract][Full Text] [Related]
6. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
Samadi P; Grégoire L; Morissette M; Calon F; Hadj Tahar A; Bélanger N; Dridi M; Bédard PJ; Di Paolo T
Neuropharmacology; 2008 Feb; 54(2):258-68. PubMed ID: 18001807
[TBL] [Abstract][Full Text] [Related]
7. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
8. DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
Bélanger N; Grégoire L; Bédard PJ; Di Paolo T
Neurobiol Aging; 2006 Nov; 27(11):1684-93. PubMed ID: 16253392
[TBL] [Abstract][Full Text] [Related]
9. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
10. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.
Huot P; Johnston TH; Winkelmolen L; Fox SH; Brotchie JM
Neurobiol Aging; 2012 Jan; 33(1):194.e5-15. PubMed ID: 20561716
[TBL] [Abstract][Full Text] [Related]
11. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Riahi G; Morissette M; Parent M; Di Paolo T
Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
[TBL] [Abstract][Full Text] [Related]
12. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
13. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
[TBL] [Abstract][Full Text] [Related]
14. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
15. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T
Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709
[TBL] [Abstract][Full Text] [Related]
16. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
18. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
19. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Huot P; Johnston TH; Koprich JB; Espinosa MC; Reyes MG; Fox SH; Brotchie JM
Behav Pharmacol; 2015 Feb; 26(1-2):101-8. PubMed ID: 25303957
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Johnston TH; Huot P; Fox SH; Wakefield JD; Sykes KA; Bartolini WP; Milne GT; Pearson JP; Brotchie JM
J Pharmacol Exp Ther; 2011 Feb; 336(2):423-30. PubMed ID: 20966038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
